Last reviewed · How we verify
Roflumilast escalation dosage
Roflumilast escalation dosage, marketed by Asan Medical Center, is a drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the lack of clear revenue data and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | Roflumilast escalation dosage |
|---|---|
| Also known as | Daxas |
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study (PHASE2)
- A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults (PHASE2)
- Strategy to Improve Adherence of Roflumilast (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |